Propofol is a short-acting intravenous sedative agent used for the induction of general anesthesia for adults and children; maintenance of general anesthesia; and sedation in medical contexts, such as intensive care unit (ICU) sedation for intubated, mechanically ventilated adults, and in procedures such as colonoscopy. It provides no analgesia.[1] Yet in some studies, when patients receive propofol compared to inhalation agents for anesthesia, postoperative pain is less after propofol.[2] Propofol is approved for use in more than 50 countries. It is also commonly used in veterinary medicine.

Methylcobalamin is a cobalamin (MeB12) used in peripheral neuropathy, diabetic neuropathy etc. It is a form of vitamin B12. It has been studied in conjunction with sleep-wake rhythm disorders, where it appears to yield benefits, but at a low or inconsistent level.

It is used in vitamin B12 deficiency (pernicious anemia) treatment

Methylcobalamin is a cobalamin (MeB12) used in peripheral neuropathy, diabetic neuropathy etc. It is a form of vitamin B12. It has been studied in conjunction with sleep-wake rhythm disorders, where it appears to yield benefits, but at a low or inconsistent level.

It is used in vitamin B12 deficiency (pernicious anemia) treatment

The invention relates to a method of preparation of 2-aminobutanol from readily available raw materials. The method of this invention is based on the reaction between 1.2-epoxybutane or isomeric butylene halogenehydrines with ammonia. The product, isomeric aminobutanols, are, subsequently transformed into 2-ethylaziridine by means of esterification with sulphuric acid followed by treatment with alkali. 2-Ethylaziridine is then submitted to a reaction with aromatic carboxylic acid or with aromatic orthobicarboxylic acid anhydride which produces the corresponding monomeric or polymeric amide, which is transformed into 2-aminobutanol by hydrolysis.

The invention relates to a method of preparation of 2-aminobutanol from readily available raw materials. The method of this invention is based on the reaction between 1.2-epoxybutane or isomeric butylene halogenehydrines with ammonia. The product, isomeric aminobutanols, are, subsequently transformed into 2-ethylaziridine by means of esterification with sulphuric acid followed by treatment with alkali. 2-Ethylaziridine is then submitted to a reaction with aromatic carboxylic acid or with aromatic orthobicarboxylic acid anhydride which produces the corresponding monomeric or polymeric amide, which is transformed into 2-aminobutanol by hydrolysis.